Anti-Aurora A/AURKA Antibody Picoband®

Overview

Anti-Aurora A/AURKA Antibody Picoband® is an antibody for AURKA detection raised in Rabbit (Polyclonal, Rabbit IgG), with reported reactivity: Human. Commonly used in WB, IHC, IF, ICC, Flow Cytometry, ELISA workflows.

Key elements and design rationale

• Target: AURKA (Probable ATP-dependent RNA helicase DDX58); UniProt: O14965
• Antibody format: Rabbit, Polyclonal, Rabbit IgG
• Molecular weight: 50 kDa, calculated 106600 MW
• Applications: WB, IHC, IF, ICC, Flow Cytometry, ELISA

Vendor description (summary): Boster Bio Anti-Aurora A/AURKA Antibody Picoband® catalog # A00246-3.

Biological background

Biological context: Innate immune receptor which acts as a cytoplasmic sensor of viral nucleic acids and plays a major role in sensing viral infection and in the activation of a cascade of antiviral responses including the induction of type I interferons and proinflammatory cytokines. Its ligands include: 5'- triphosphorylated ssRNA and dsRNA and short dsRNA (<1 kb in length). In addition to the 5'-triphosphate moiety, blunt-end base pairing at the 5'-end of the RNA is very essential. Overhangs at the non-triphosphorylated end of the dsRNA RNA have no major impact on its activity. A 3'overhang at the 5'triphosphate end decreases and any 5'overhang at the 5' triphosphate end abolishes its activity. Upon ligand binding it associates with mitochondria antiviral signaling protein (MAVS/IPS1) which activates the IKK- related kinases: TBK1 and IKBKE which phosphorylate interferon regulatory factors: IRF3 and IRF7 which in turn activate transcription of antiviral immunological genes, including interferons (IFNs); IFN-alpha and IFN-beta. Detects both positive and negative strand RNA viruses including members of the families Paramyxoviridae: Human respiratory syncytial virus and measles virus (MeV), Rhabdoviridae: vesicular stomatitis virus (VSV), Orthomyxoviridae: influenza A and B virus, Flaviviridae: Japanese encephalitis virus (JEV), hepatitis C virus (HCV), dengue virus (DENV) and west Nile virus (WNV). It also detects rotavirus and reovirus. Also involved in antiviral signaling in response to viruses containing a dsDNA genome such as Epstein-Barr virus (EBV). Detects dsRNA produced from non-self dsDNA by RNA polymerase III, such as Epstein-Barr virus-encoded RNAs (EBERs). May play important roles in granulocyte production and differentiation, bacterial phagocytosis and in the regulation of cell migration. .

Expression and localization notes: cellular localization: Cytoplasm. Cell projection, ruffle membrane. Cytoplasm, cytoskeleton. Cell junction, tight junction. Colocalized with TRIM25 at cytoplasmic perinuclear bodies. Associated with the actin cytoskeleton at membrane ruffles., tissue context: Present in vascular smooth cells (at protein level). ..

Common research applications

• Western blotting (WB): Compare AURKA levels across samples and conditions using appropriate loading and biological controls.
• Immunohistochemistry (IHC): Evaluate spatial distribution of AURKA in tissue sections, considering fixation and antigen retrieval effects.
• Immunofluorescence / ICC: Assess subcellular localization patterns and co-localization with compartment markers in cultured cells.
• Flow cytometry: Quantify AURKA-positive populations in single-cell suspensions with appropriate gating and controls.
• ELISA: Use antibody-based detection formats to assess antigen presence or binding in plate-based assays.

Notes for experimental interpretation

• Account for isoforms, post-translational modifications, and sample-specific processing that can shift apparent molecular weight or epitope accessibility.
• Use positive/negative biological controls where possible (e.g., known-expressing cells/tissues, knockdown/knockout models) and include appropriate secondary-only/isotype controls for imaging workflows.

Additional product notes (from provided fields)

• Background: AURKA(aurora kinase A), also called ARK1, AurA, AIK , AURORA2 ,BTAK, PPP1R47, STK7, STK15,STK6, is a mitotic centrosomal protein kinase. The main role of AURKA in tumor development is in controlling chromosome segregation during mitosis. Aurora A is a member of a family of mitotic serine/threonine kinases. Cell cycle and Northern blot analyses showed that peak expression of AURKA occurs during the G2/M phase and then decreases. By fluorescence in situ hybridization, AURKA gene is represented by 2 signals in chromosome bands 20q13.2-q13.3 and 1q41-q42. The AURKA gene is overexpressed in many human cancers. Ectopic overexpression of Aurora kinase A in mammalian cells induces centrosome amplification, chromosome instability, and oncogenic transformation, a phenotype characteristic of loss-of-function mutations of p53. Depletion of Ajuba prevented activation of AURKA at centrosomes in late G2 phase and inhibited mitotic entry. Activation of AURKA was independently sufficient to induce rapid ciliary resorption, and AURKA acted in this process through phosphorylation of HDAC6, leading to HDAC6-dependent tubulin deacetylation and destabilization of the ciliary axoneme. Small molecule inhibitors of AURKA and HDAC6 reduced regulated disassembly of cilia.
• Cross reactivity: No cross-reactivity with other proteins.
• Cellular localization: Cytoplasm. Cell projection, ruffle membrane. Cytoplasm, cytoskeleton. Cell junction, tight junction. Colocalized with TRIM25 at cytoplasmic perinuclear bodies. Associated with the actin cytoskeleton at membrane ruffles.
• Tissue details: Present in vascular smooth cells (at protein level). .
• Research category: Antiviral Signaling,Chromatin Binding Proteins,DNA/RNA,DNA/RNA Binding,Epigenetics and Nuclear Signaling,Immune System Diseases,Immunology,RNA Processing

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.